Full disclaimer 1.Retatrutide (LY3437943) is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly 2.Phase 2 trials demonstrated up to 24.2% body weight loss at 48 weeksthe highest weight loss ever reported in a Phase 2 obesity trial 3.Triple mechanism activates multiple metabolic pathways: appetite suppression (GLP-1), improved insulin sensitivity (GIP), and increased energy expenditure (glucagon) 4.Currently in Phase 3 TRIUMPH trials for weight management, type 2 diabetes, NASH, and osteoarthritis
Scientific consensus has yet to be reached on whether the combination of paracetamol and ibuprofen produces an enhanced painkilling effect
The treatment destroys localised body fat cells for good
Supplements There are three key therapeutic dietary supplements for PCOS: Inositol , Berberine , and L-Carnitine
GLP-1 medications can be both supportive and challenging when planning surgery